title: Effects of chronic risperidone treatment on the striatal protein profiles in rats.
abstract: Extrapyramidal symptoms (EPS) commonly occur as side effects of antipsychotic drugs (APDs) and are most likely to arise when the occupancy of dopamine D(2) receptors in the striatum by these drugs exceeds 80%. We aimed to characterize changes in the protein expression profile in the striatum of rats after chronic (4 week) supra-therapeutic (EPS-inducing) treatment with risperidone (RIS), an atypical antipsychotic drug. Administration of RIS (2.1 mg/kg/day, via subcutaneous osmotic minipumps) induced significant vacuous chewing movements and catalepsy in male Sprague-Dawley rats over a 28-day treatment period compared with a vehicle (VEH) control group (n=12) (Karl et al., unpublished observation). Using two-dimensional gel electrophoresis (2DE), total protein extracts from the rat brain striatum were separated and protein expression was analyzed by Phoretix 2D Expression and Image Beta V4.02 software followed by matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). 2DE gels resolved up to 450 protein spots, presumably different proteins and/or their isoforms. There were 30 protein spots showing statistically significant different densities between the RIS- and VEH-treated groups. All 30 proteins were successfully identified by MALDI-TOF MS, 28 of these were divided into groups based on their known functions. These included metabolic, signaling, transport, protein metabolism, chaperone, DNA binding and cell cycle categories. We conclude that chronic risperidone treatment accompanied by an EPS-like behavioral phenotype results in alterations in the striatal protein profile possibly subsequent to blockade of dopaminergic systems. These results suggest that possible mechanisms involved in APD-induced EPS include metabolic dysfunction and oxidative stress.
authors.affiliation: Discipline of Pathology, Blackburn Building, D06, The University of Sydney, NSW, 2006, Australia.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: O'Brien
authors.forename: Irina
authors.initials: I
authors.lastname: Dedova
authors.forename: Liesl
authors.initials: L
authors.lastname: Duffy
authors.forename: Stuart
authors.initials: S
authors.lastname: Cordwell
authors.forename: Tim
authors.initials: T
authors.lastname: Karl
authors.forename: Izuru
authors.initials: I
authors.lastname: Matsumoto
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001522:Behavior, Animal; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D003952:Diagnostic Imaging / Q000379:methods; D004334:Drug Administration Schedule; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D011506:Proteins / Q000378:metabolism*; D040901:Proteomics / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D018967:Risperidone / Q000008:administration & dosage*
chemical_list: D014150:Antipsychotic Agents; D011506:Proteins; D018967:Risperidone